PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity
- PMID: 14577579
- DOI: 10.1023/a:1025566919581
PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity
Abstract
This study investigated the effects of PD-136,450 (PD), a highly selective ligand for the CCK2 receptor, on gastric acid and pancreatic secretions, gastric cytoprotection and anxious behaviour in the rat and rabbit. PD inhibited gastrin (but not dimaprit) stimulated acid secretion in anaesthetized and conscious rats (IC50 of 1 mg kg(-1) sc) and inhibited 14C-aminopyrine uptake in isolated gastric glands from rabbits. In addition, PD decreased dose-dependently gastric haemorrhagic lesions in rats treated orally with acidified ethanol. Both, the antisecretory effects on gastric acid secretion and the gastric cytoprotective effects were less potent compared with the proton pump inhibitor omeprazole. PD strongly increased pancreatic secretion, which was substantially inhibited by the CCK1 antagonist L-364,718 (but not by the CCK2 antagonist L-365,260). PD also showed significant anxiolytic activity as assessed by a black and white box two-compartment activity assay. Both, time spent in the dark compartment and latency for movement from the light to the dark compartment was increased by PD (similarly with 5 mg kg(-1) diazepam). In conclusion, PD inhibited gastrin-stimulated gastric acid secretion, decreased ethanol-induced damage to the gastric mucosa, stimulated pancreatic secretion (via CCK1 receptors) and displayed anxiolytic activity. Thus, PD may have utility as an adjunct therapy in peptic ulcer disease by countering the actions of gastrin and increasing acid neutralization and mucosal protection.
Similar articles
-
Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat.Gut. 1994 Feb;35(2):270-4. doi: 10.1136/gut.35.2.270. Gut. 1994. PMID: 8307482 Free PMC article.
-
Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.Eur J Pharmacol. 1999 Mar 12;369(1):81-90. doi: 10.1016/s0014-2999(99)00069-2. Eur J Pharmacol. 1999. PMID: 10204685
-
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.J Pharmacol Exp Ther. 1994 Sep;270(3):1256-61. J Pharmacol Exp Ther. 1994. PMID: 7932178
-
[Gastrin/CCK-B receptor antagonists for a novel antiulcer agent].Nihon Yakurigaku Zasshi. 1995 Sep;106(3):171-80. doi: 10.1254/fpj.106.171. Nihon Yakurigaku Zasshi. 1995. PMID: 8529962 Review. Japanese.
-
Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).Curr Pharm Des. 2013;19(1):84-9. doi: 10.2174/13816128130112. Curr Pharm Des. 2013. PMID: 22946903 Review.
Cited by
-
Chemical constituents and medicinal properties of Allium species.Mol Cell Biochem. 2021 Dec;476(12):4301-4321. doi: 10.1007/s11010-021-04213-2. Epub 2021 Aug 21. Mol Cell Biochem. 2021. PMID: 34420186 Review.
-
Influence of the Novel Histamine H3 Receptor Antagonist/Inverse Agonist M39 on Gastroprotection and PGE2 Production Induced by (R)-Alpha-Methylhistamine in C57BL/6 Mice.Front Pharmacol. 2019 Sep 12;10:966. doi: 10.3389/fphar.2019.00966. eCollection 2019. Front Pharmacol. 2019. PMID: 31572174 Free PMC article.